AURA

Aura Biosciences Inc

6.14

Oct 30 • 3:59 PM ET -0.16 (-2.46%)

6.14

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: IDYA IMCR CGON DCTH URGN CADL OCUL REPL EYPT KOD

| Held by: VTI IWM VXF XBI IBB IWO FESM VTWO DFAS VHT

Scroll to Statements

Index	RUT
Market Cap	636.75M
Enterprise Value	329.50M
Income	-131.01M
Sales	0.00M
Book/sh	3.05
Cash/sh	3.12
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	113
IPO	Oct 29, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.02
P/C	1.97
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	16.82
Current Ratio	16.82
Debt/Eq	0.05
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-1.78
EPS next Y	-1.52
EPS next Q	-0.37
EPS this Y	5.38%
EPS next Y	8.84%
EPS next 5Y	12.07%
EPS past 3/5Y	3.57% -11.28%
Sales past 3/5Y	- -
EPS Y/Y TTM	9.05%
Sales Y/Y TTM	-
EPS Q/Q	-3.31%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-28.00% -

Insider Own	59.80%
Insider Trans	-10.06%
Inst Own	64.24%
Inst Trans	33.52%
ROA	-47.42%
ROE	-53.49%
ROIC	-39.87%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.08%
SMA50	-8.09%
SMA200	-8.58%
Trades

Shs Outstand	103.48M
Shs Float	41.69M
Short Float	26.11%
Short Ratio	12.72
Short Interest	10.89M
52W High	9.53 -35.61%
52W Low	4.73 29.81%
Volatility	4.37% 4.50%
ATR (14)	0.29
RSI (14)	42.64
Beta	0.41
Rel Volume	0.62
Avg Volume	855.84K
Volume	533,027

Perf Week	-2.54%
Perf Month	1.66%
Perf Quarter	-12.78%
Perf Half Y	-12.41%
Perf YTD	12.66%
Perf Year	0.99%
Perf 3Y	-17.80%
Perf 5Y	-58.51%
Perf 10Y	-
Recom	1.00
Target Price	16.60
Prev Close	6.30
Price	6.14
Change %	-2.46%

Consensus

Strong Buy

Avg. Price Target

$16.60

Implied Upside

+170.4%

Analysts5incl. previous ratings

Rating Distribution5 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 26, 2025	Resumed	EEvercore ISI	Outperform	$13	+111.7%
May 28, 2025	Resumed	HH.C. Wainwright	Buy	$22	+258.3%
Jul 25, 2024	Initiated	HH.C. Wainwright	Buy	$21	+242.0%
Jul 27, 2023	Initiated	BScotiabank	Sector Outperform
Apr 17, 2023	Resumed	BBTIG Research	Buy	$38	+518.9%
Jul 19, 2022	Initiated	JJMP Securities	Mkt Outperform	$26	+323.5%

Sep-02-26 04:01PM	Aura Biosciences to Participate in Upcoming Investor Conference (GlobeNewswire)
Sep-01-26 04:28PM	Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-26 07:00AM	Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-08-26 07:01AM	Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors (GlobeNewswire)
Jun-01-26 08:00AM	Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma (GlobeNewswire)
04:50PM	Loading…
May-19-26 04:50PM	Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-12-26 04:01PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-11-26 04:01PM	Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
May-05-26 05:15PM	Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +6.59% -6.85%
May-04-26 09:03AM	Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants (GlobeNewswire) +19.12%
06:03AM	Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:01AM	Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion (GlobeNewswire)
Apr-07-26 05:15PM	Auranova Announces Closing of Private Placement of Flow-Through Shares (TMX Newsfile)
Apr-01-26 07:30AM	Auranova Resources and Kenorland Minerals Commence Spring Drill Program at South Uchi Project (TMX Newsfile)
Mar-30-26 07:00AM	Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
10:28AM	Loading…
Mar-18-26 10:28AM	Auranova Resources and Kenorland Minerals Announce Upcoming 2026 Spring Drill Program at The South Uchi Project, Ontario (TMX Newsfile)
Mar-05-26 01:33AM	Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference (MarketBeat) -7.32%
Mar-04-26 09:40AM	Is Assertio (ASRT) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-25-26 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.99%
Feb-16-26 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Feb-13-26 12:00PM	What Makes Aura Biosciences (AURA) a New Buy Stock (Zacks)
Nov-24-25 04:05PM	Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +11.09%
Nov-13-25 07:00AM	Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Sep-03-25 07:00AM	Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-13-25 07:00AM	Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Jul-29-25 04:53PM	4 Artificial Intelligence Stocks (That Aren't Nvidia) You Can Buy and Hold for the Next Decade (Motley Fool)
May-15-25 09:32AM	Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire) +5.71%
06:10AM	Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
06:01AM	Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-01-25 04:01PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:35PM	Loading…
Apr-06-25 04:35PM	Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential? (Insider Monkey)
Apr-02-25 07:00AM	Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors (GlobeNewswire)
Mar-25-25 06:58PM	Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript) (SeekingAlpha) -15.40%
Mar-24-25 04:01PM	Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) -6.67%
07:00AM	Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress (GlobeNewswire)
Mar-03-25 07:00AM	Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress (GlobeNewswire)
Feb-25-25 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-26-24 08:00AM	Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-12-24 04:05PM	Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Oct-17-24 04:05PM	Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial (GlobeNewswire) +14.09%
Sep-12-24 06:30AM	Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma (GlobeNewswire) +7.94%
Sep-03-24 04:05PM	Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 (GlobeNewswire) -7.04%
Aug-28-24 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-24 04:05PM	Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting (GlobeNewswire)
Aug-08-24 07:00AM	Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-06-24 09:55AM	Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High? (Zacks)
May-30-24 04:05PM	Aura Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 08:00AM	Aura Biosciences to Host Virtual KOL Event Pioneering a New Standard of Care In Ocular Oncology on May 29, 2024 (GlobeNewswire)
May-10-24 02:58PM	Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:55PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-08-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-27-24 01:53PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-26-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-11-23 09:55AM	Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet (Zacks) -8.46%
Dec-07-23 08:00AM	Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma (Business Wire)
Nov-23-23 09:55AM	Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade (Zacks)
Nov-09-23 04:05PM	Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +9.54%
Nov-08-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-06-23 10:02PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -8.18% -32.55%
04:08PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
03:00PM	Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma (Business Wire)
Oct-31-23 04:05PM	Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023 (Business Wire) +9.24% +9.93%
Oct-02-23 04:05PM	Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments (Business Wire) -7.47%
Aug-09-23 07:00AM	Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -6.62%
Jul-31-23 06:07AM	Owning 38% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA), (Simply Wall St.)
May-24-23 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire) -5.29%
May-12-23 07:00AM	Aura Biosciences to Participate in the JMP Securities Life Sciences Conference (Business Wire)
May-11-23 04:10PM	Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
May-03-23 07:52AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Mar-15-23 04:10PM	Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
11:11AM	Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth (Simply Wall St.)
Feb-16-23 10:43AM	Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate (Benzinga) -7.17%
07:00AM	Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration (Business Wire)
Feb-10-23 06:03AM	Why Shares of Aura Biosciences Jumped This Week (Motley Fool)
Feb-09-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-24-22 09:27AM	Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 11% drop adds to a year losses (Simply Wall St.)
Dec-16-22 09:54AM	12 Stocks Insiders are Buying Now (Insider Monkey)
Nov-30-22 08:50PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -6.02%
04:01PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-24-22 06:34AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Nov-10-22 07:00AM	Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
06:45AM	Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma (Business Wire)
Nov-03-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Oct-06-22 10:12AM	Here's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Situation (Simply Wall St.)
Oct-04-22 07:05AM	Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedicals Proprietary Suprachoroidal Space Platform (GlobeNewswire)
Oct-03-22 01:37PM	Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug (Benzinga) -19.48%
07:00AM	Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 (Business Wire)
Sep-28-22 07:00AM	Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire) +19.23%
Sep-27-22 07:00AM	Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 (Business Wire) +5.12%
Sep-07-22 07:00AM	Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress (Business Wire)
Sep-01-22 07:00AM	Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress (Business Wire)
Aug-11-22 04:15PM	Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -8.60% +8.89%
Aug-02-22 07:00AM	Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference (Business Wire)
Jul-19-22 03:04PM	JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer" (Benzinga) +7.67%
Jul-17-22 08:36AM	Could The Aura Biosciences, Inc. (NASDAQ:AURA) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jun-30-22 08:51AM	Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate (MarketWatch) +12.73%
07:00AM	Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibney Anthony	Officer	Jun 16 '26	Proposed Sale	6.42	12,824	82,330		Jun 16 04:30 PM
Gibney Anthony S	See Remarks	Jun 16 '26	Sale	6.42	12,824	82,330	265,354	Jun 16 04:30 PM
Matrix Capital Management Comp	10% Owner	May 07 '26	Sale	5.64	6,922,870	39,044,987	0	May 11 04:16 PM
Kilroy Conor	Officer	Apr 16 '26	Proposed Sale	7.02	11,738	82,402		Apr 16 06:50 PM
Kilroy Conor	See Remarks	Apr 16 '26	Sale	7.02	11,738	82,401	217,835	Apr 16 06:49 PM
Kilroy Conor	Officer	Feb 17 '26	Proposed Sale	5.05	12,079	61,037		Feb 17 07:51 PM
Plavsic Mark	Officer	Feb 17 '26	Proposed Sale	5.05	15,890	80,271		Feb 17 07:50 PM
Hopkins Janet Jill	Officer	Feb 17 '26	Proposed Sale	5.06	20,401	103,231		Feb 17 07:50 PM
Elazzouzi Amy	Officer	Feb 17 '26	Proposed Sale	5.06	8,549	43,261		Feb 17 07:50 PM
de los Pinos Elisabet	Officer	Feb 17 '26	Proposed Sale	5.06	47,648	241,063		Feb 17 07:49 PM
Kilroy Conor	See Remarks	Feb 17 '26	Sale	5.05	12,079	60,999	167,234	Feb 17 07:48 PM
Plavsic Mark	Chief Technology Officer	Feb 17 '26	Sale	5.05	15,890	80,244	181,397	Feb 17 07:47 PM
Hopkins Janet Jill	Chief Medical Officer	Feb 17 '26	Sale	5.06	20,401	103,229	232,284	Feb 17 07:47 PM
Elazzouzi Amy	Senior Vice President, Finance	Feb 17 '26	Sale	5.06	8,549	43,258	75,532	Feb 17 07:47 PM
de los Pinos Elisabet	See Remarks	Feb 17 '26	Sale	5.06	47,648	241,099	409,815	Feb 17 07:46 PM
Elazzouzi Amy	Officer	Jan 20 '26	Proposed Sale	4.86	1,581	7,684		Jan 20 06:42 PM
de los Pinos Elisabet	Officer	Jan 20 '26	Proposed Sale	4.86	16,928	82,234		Jan 20 06:42 PM
Elazzouzi Amy	Senior Vice President, Finance	Jan 20 '26	Sale	4.86	1,581	7,684	84,081	Jan 20 06:41 PM
de los Pinos Elisabet	See Remarks	Jan 20 '26	Sale	4.86	16,928	82,270	457,463	Jan 20 06:41 PM
Hopkins Janet Jill	Officer	Nov 17 '25	Proposed Sale	5.42	17,109	92,735		Nov 17 05:57 PM
Hopkins Janet Jill	Chief Medical Officer	Nov 17 '25	Sale	5.42	17,109	92,731	252,685	Nov 17 05:56 PM

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Chief Medical Officer & President of Research and DevelopmentDr. J. Jill Hopkins M.D.

PresidentMs. Natalie C. Holles

Senior Vice President of FinanceMs. Amy Elazzouzi

Chief Operating OfficerMs. Susan Abu-Absi Ph.D.

Head of Investor Relations & Corporate CommunicationsAlex Dasalla

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AURA

Aura Biosciences Inc

Upgrade your Finviz experience